Prestige BioPharma Limited (950210.KS) KSC
Currency In KRW
- General
- Statistics
- Historical Data
- Profile
- Financials
Prestige BioPharma Limited
Address
#04-24 Nucleos South Building
Singapore, CE 138567
Singapore
Phone
65 6924 6535
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
February 09, 2021
Key Executives
| Name | Title | Pay | Year Born |
| So-Yeon Park | Chairman & Chief Executive Officer | 759.31M | 1963 |
| Jinwoo Kim | Vice Chairman of the Board & CFO | 704.33M | 1964 |
| Dong -Jo Shin | Head of Finance | 0 | 1973 |
| Ghislain M.C Bonamy | General Manager of Licensing | 0 | 1979 |
| Michael Ruppert | Head of Business Development | 0 | 1967 |
| Kay Lee | Clinical Development Manager | 0 | 1970 |
| Sumiko Shiba | Secretary | 0 | 1982 |
| Neil O'Connor | CMCB Head | 0 | N/A |
| Sumita Pradhan | R&MA Head | 0 | N/A |
Description
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.
